NMD Pharma's new treatment shows promise in improving muscle function for neuromuscular diseases.

NMD Pharma has shown promising results in preclinical studies for a new treatment of neuromuscular diseases. The treatment, a ClC-1 ion channel inhibitor, improved muscle function and increased the number of fully innervated muscle fibers in a rat model with myasthenia gravis. This could lead to new therapies for rare neuromuscular disorders and age-related muscle diseases.